Group 1: IPO Applications - Maiwei Biotech, Jitai Technology, and Xinghuan Technology have submitted their listing applications to the Hong Kong Stock Exchange [1] - Maiwei Biotech is known for its drug research and development capabilities, covering the entire process from drug discovery to commercialization [1] - Jitai Technology is a leader in AI nanomaterials innovation, focusing on effective payload delivery across all life forms [1] - Xinghuan Technology is one of the first companies in China to specialize in AI and big data infrastructure software development, offering enterprise-level AI infrastructure software and services [1] Group 2: Financial Performance - Xtep International reported a 4.2% increase in revenue to 14.15 billion yuan for the fiscal year 2025, with net profit rising by 10.8% to 1.372 billion yuan [2] - The board of Xtep International proposed a final dividend of 0.095 HKD per share, with a total payout ratio of 50.4% [2] - Kangchen Pharmaceutical achieved a revenue of 3.417 billion yuan, a year-on-year increase of 15.17%, with net profit attributable to shareholders rising by 18.41% to 1.078 billion yuan [3] - Kuaishou reported total revenue of 142.8 billion yuan for 2025, a 12.5% year-on-year growth, with adjusted net profit increasing by 16.5% to 20.6 billion yuan [4] - Kuaishou's revenue from online marketing services reached 81.462 billion yuan, driven by the accelerated penetration and innovative applications of AI [4] Group 3: Market Performance - The Hang Seng Index closed at 24,856.43, down 1.89% on March 26 [5] - The Hang Seng Tech Index fell by 3.28% to 4,761.54 [5] - The Hang Seng China Enterprises Index decreased by 2.25% to 8,389.93 [5]

EF001 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事局由執行董事安猛先生及楊玉川先生；非執行董事張麗華博士及朱荃教授；獨立非執行董事馮仲實先生、李義 凱教授、李灼光先生及段威武先生組成。 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 康臣葯業集團有限公司 | | 股份代號 | 01681 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | ...

Financial Performance - For the year ended December 31, 2025, the revenue was RMB 3,417,355,000, an increase of approximately 15.2% compared to RMB 2,967,235,000 for the year ended December 31, 2024[4] - The profit attributable to equity shareholders for the year ended December 31, 2025, was RMB 1,078,067,000, representing an increase of approximately 18.4% from RMB 910,458,000 for the year ended December 31, 2024[4] - Basic and diluted earnings per share for the year ended December 31, 2025, were approximately RMB 1.27 and RMB 1.26, respectively, reflecting increases of about 14.4% and 15.6% from RMB 1.11 and RMB 1.09 for the year ended December 31, 2024[4] - The total comprehensive income for the year ended December 31, 2025, was RMB 1,089,750,000, compared to RMB 917,551,000 for the year ended December 31, 2024[6] - The operating profit for the year ended December 31, 2025, was RMB 1,202,379,000, compared to RMB 1,045,060,000 for the year ended December 31, 2024[5] - Pre-tax profit for 2025 was RMB 1,196,422,000, an increase from RMB 1,020,106,000 in 2024, representing a growth of approximately 17.3%[34] - The gross profit for 2025 was RMB 2,667,120,000, an increase of about 19.0% from RMB 2,242,102,000 in 2024, with a gross margin of approximately 78.0%, up 2.4 percentage points from 75.6%[79] Assets and Liabilities - The total assets less current liabilities as of December 31, 2025, amounted to RMB 4,979,706,000, an increase from RMB 4,482,282,000 as of December 31, 2024[8] - The net asset value as of December 31, 2025, was RMB 4,837,870,000, compared to RMB 4,393,052,000 as of December 31, 2024[8] - The total assets for reportable segments rose to RMB 6,296,016,000 in 2025, compared to RMB 5,851,628,000 in 2024, marking an increase of 7.6%[22] - The total bank loans amounted to RMB 200,000,000, a decrease from RMB 253,340,000 in 2024[63] - The total lease liabilities as of December 31, 2025, were RMB 12,920,000, compared to RMB 13,829,000 in 2024[64] Dividends - The company proposed a final dividend of HKD 0.40 per share for the year ended December 31, 2025[4] - The interim dividend per share for ordinary shares is HKD 0.33 for 2025, an increase from HKD 0.30 in 2024, totaling RMB 253,308,000, compared to RMB 229,827,000 in 2024[38] - The proposed final dividend per share for ordinary shares is HKD 0.40 for 2025, up from HKD 0.30 in 2024, amounting to RMB 296,201,000, compared to RMB 235,954,000 in 2024[38] Costs and Expenses - The financing costs for the year ended December 31, 2025, were RMB 4,360,000, significantly reduced from RMB 24,888,000 for the year ended December 31, 2024[5] - Employee costs rose to RMB 678,611,000 in 2025 from RMB 593,172,000 in 2024, reflecting an increase of about 14.4%[4] - Administrative expenses increased by approximately 42.9% to RMB 445,631,000 in 2025, up from RMB 311,873,000 in 2024, mainly due to organizational restructuring and increased R&D expenses[82] - Distribution costs rose by approximately 9.3% to RMB 1,072,775,000 in 2025, compared to RMB 981,576,000 in 2024, with the growth rate significantly lower than revenue growth[81] Research and Development - Research and development costs for 2025 amounted to RMB 151,844,000, up from RMB 97,541,000 in 2024, indicating a significant increase of approximately 55.6%[29] - The group made significant progress in R&D, with SK-08 and SK-09 receiving IND approval from the FDA, marking a breakthrough in global drug development[70] - The group launched a multi-modal AIDD platform to optimize drug design and reduce development costs, enhancing R&D efficiency[70] - The establishment of an international scientific advisory board aims to enhance the development of new drugs for chronic kidney disease, with Dr. Jonathan Barratt as the first advisor[71] Inventory and Receivables - The company reported a decrease in inventory to RMB 271,405,000 as of December 31, 2025, from RMB 289,677,000 as of December 31, 2024[7] - Trade receivables, net of impairment, increased to RMB 251,321,000 in 2025 from RMB 234,186,000 in 2024[56] - As of December 31, 2025, inventory balance was RMB 271,405,000, a decrease of approximately 6.3% compared to RMB 289,677,000 on December 31, 2024, with inventory turnover days reduced by 28.8 days to 136.5 days[87] Corporate Governance and Compliance - The company has maintained compliance with relevant laws and regulations without any significant violations for the year ending December 31, 2025[109] - The audit committee, composed of three independent non-executive directors, has reviewed the financial controls and risk management systems to ensure effective oversight[115] - The company has adopted corporate governance principles and standards, aiming for continuous improvement in compliance efficiency and effectiveness[111] - The roles of the chairman and CEO have been clearly delineated to enhance independence and ensure a balance of power and authority[112] Market and Industry Trends - The company experienced a significant shift in the pharmaceutical industry towards value creation rather than scale expansion due to regulatory changes[66] - The overall growth rate of the industry is slowing, but structural opportunities remain for innovative and irreplaceable products and services[66] - The company has been closely monitoring recent developments in national policies affecting the pharmaceutical industry, which are considered major uncertainties[107] Cash Flow and Financing - Net cash generated from operating activities for 2025 was RMB 1,211,796,000, an increase of approximately 11.5% from RMB 1,086,987,000 in 2024[90] - Cash and bank balances, including financial products, increased by approximately 13.4% to RMB 4,383,691,000 as of December 31, 2025[91] - The capital debt ratio decreased by 1.8 percentage points to 4.4% as of December 31, 2025, due to a reduction in net bank loans and an increase in equity attributable to shareholders[94] Shareholder Information - The board proposed a final dividend of HKD 0.4 per share for the year ending December 31, 2025, subject to shareholder approval at the annual general meeting on May 26, 2026[121] - The final dividend, if approved, is expected to be paid on or around June 22, 2026, to shareholders listed on the register as of June 10, 2026[121] - Shareholders must submit completed share transfer documents by 4:30 PM on May 19, 2026, to be eligible to attend and vote at the annual general meeting[122]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 康臣葯業集團有限公司 主席 安猛 香港，2026年3月5日 於本公告日期，董事局由執行董事安猛先生及楊玉川先生；非執行董事張麗華博 士及朱荃教授；獨立非執行董事馮仲實先生、李義凱教授、李灼光先生及段威武 先生組成。 1. 審閱及批准本公司及其附屬公司（統稱「本集團」）截至2025年12月31日止年 度經審核綜合財務報表（「年度業績」）； 2. 審閱及批准將根據香港聯合交易所有限公司證券上市規則公佈之本集團年度 業績公告草案； 3. 考慮派發末期股息（如有）； 4. 考慮召開本公司應屆股東周年大會的相關事宜；及 5. 考慮及批准其他事項（如有）。 （於開曼群島註冊成立的有限公司） （股份代號：1681） 董事局會議通告 康臣葯業集團有限公司（「本公司」）董事局（「董事局」）謹此宣佈，本公司將於 2026年3月26日（星期四）舉行董事局會議，以處理以下事項： 承董事局命 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康臣葯業集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - 康臣药业's stock price has seen a significant increase, reaching a high of 19.49 HKD, following its inclusion in the Hang Seng Composite Index, which is expected to enhance its market visibility and liquidity [1] Group 1: Stock Performance - 康臣药业's stock price rose by 6.97%, trading at 19.35 HKD with a transaction volume of 37.8752 million HKD [1] - The stock experienced an intraday increase of over 7%, marking a new high [1] Group 2: Index Inclusion - On February 13, the Hang Seng Index Company announced that 康臣药业 will be included in the Hang Seng Composite Index, effective March 9, 2026 [1] - This inclusion is anticipated to lead to adjustments in the Hong Kong Stock Connect investment scope, as 康臣药业 meets various criteria such as market capitalization, liquidity, and listing duration [1] Group 3: Share Buyback Plan - 康臣药业's board has approved an additional share buyback plan, allocating up to 100 million HKD for repurchasing shares in the open market, on top of a previous buyback plan [1] - The total funds earmarked for the share buyback plan will not exceed 300 million HKD, reflecting the board's confidence in the company's business development and future prospects [1]

Group 1 - The core viewpoint of the article highlights that Kangchen Pharmaceutical (01681) has seen a significant stock price increase, rising over 7% to reach a new high of 19.49 HKD, with a trading volume of 31.34 million HKD [1] - On February 13, the Hang Seng Index Company announced that Kangchen Pharmaceutical will be included in the Hang Seng Composite Index as of December 31, 2025, with changes effective after market close on March 6, 2026, and starting from March 9, 2026 [1] - According to a report from CICC, Kangchen Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] Group 2 - The company announced a new share buyback plan, adding up to 100 million HKD to the previously authorized buyback, bringing the total planned expenditure for share repurchases to no more than 300 million HKD [1] - The board of directors expresses confidence in the company's business development and future prospects, believing that the current stock price does not fully reflect its intrinsic value and long-term growth potential [1]

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Kang Hsin Pharmaceutical (01681) being included in the Hang Seng Composite Index, effective after market close on March 6, 2026, and effective from March 9, 2026 [1] Group 1 - The inclusion of Kang Hsin Pharmaceutical in the Hang Seng Composite Index will lead to adjustments in the investable universe of Hong Kong Stock Connect by the Shanghai and Shenzhen Stock Exchanges [1] - According to a report by CICC, Kang Hsin Pharmaceutical is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing duration [1] Group 2 - Kang Hsin Pharmaceutical previously announced on June 13, 2025, that its board of directors resolved to execute a share buyback plan with a total fund not exceeding HKD 200 million for repurchasing shares in the open market [1] - On January 29, 2026, the board further resolved to execute an additional share buyback plan with a maximum additional fund of HKD 100 million, bringing the total planned expenditure for share buybacks to not exceed HKD 300 million [1] - The duration of the share buyback plan will last from the date of the announcement until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization at the general meeting [1]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Kangchen Pharmaceutical (01681) being included in the Hang Seng Composite Index, effective from March 9, 2026 [1] Group 1: Index Inclusion - Kangchen Pharmaceutical will be added to the Hang Seng Composite Index, with the change taking effect after market close on March 6, 2026 [1] - The inclusion may lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1] Group 2: Share Buyback Plans - Kangchen Pharmaceutical's board has resolved to execute a share buyback plan with a total fund limit of up to HKD 200 million, to be conducted in the open market [1] - On January 29, 2026, the board approved an additional share buyback plan, increasing the total fund limit by up to HKD 100 million, bringing the total potential fund for share buybacks to a maximum of HKD 300 million [1] - The duration of the share buyback plan will last until the conclusion of the next annual general meeting or until the shareholders withdraw or amend the buyback authorization [1]

Group 1 - The company, 康臣药业 (01681), announced the cancellation of 100,000 shares that were repurchased, effective on February 12, 2026 [1]